EnVivo Pharmaceuticals

EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, and Schizophrenia. The company’s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for cognitive enhancement in Alzheimer’s disease and Schizophrenia, a Histone Deacetylase (HDAC) Inhibitor Program for cognitive enhancement in Alzheimer’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phospho-Diesterase 10 (PDE10) Program for Schizophrenia.

EnVivo News & Events

EnVivo Pharmaceuticals announced today that it has initiated a clinical safety and biomarker study of its alpha-7 nicotinic agonist (EVP-6124) in Schizophrenia patients chronically treated with atypical antipsychotic medications.

Montreal, Quebec and Watertown, MA. February 6, 2008 – MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals today announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005.

Latest Posts

Generic Viagra Online – Alternative for the purchase of Viagra.

The safe use of Kamagra Oral Jelly has been reviewed, recognized and used by many around the world.

The Viagra professional is an improved form of the original Viagra.

Sildenafil citrate is a generic medicine prescribed in cases of erectile dysfunction.

Caverta is available in 20 mg, 50 mg, and 100 mg oral pill